Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Kanakry CG, et al. Among authors: borrello i. Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14. Blood. 2014. PMID: 25316679 Free PMC article.
New Developments in the Therapy of Acute Myelocytic Leukemia.
Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S. Gorin NC, et al. Among authors: borrello i. Hematology Am Soc Hematol Educ Program. 2000:69-89. doi: 10.1182/asheducation-2000.1.69. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701536
This review examines the search for new agents and new modes of therapy. In Section I, Dr. Estey discusses new agents directed at various targets, such as CD33, angiogenesis, inappropriately methylated (suppressor) genes, cell cycle checkpoints, proteosomes, multidrug resi …
This review examines the search for new agents and new modes of therapy. In Section I, Dr. Estey discusses new agents directed at var …
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ. Huff CA, et al. Among authors: borrello i. Biol Blood Marrow Transplant. 2003 May;9(5):312-9. doi: 10.1016/s1083-8791(03)00075-2. Biol Blood Marrow Transplant. 2003. PMID: 12766881 Free article.
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Huff CA, et al. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-21. doi: 10.1016/j.bbmt.2005.11.520. Biol Blood Marrow Transplant. 2006. PMID: 16545725 Free article. Clinical Trial.
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.
Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Bolaños-Meade J, et al. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-91. doi: 10.1016/j.bbmt.2007.06.011. Epub 2007 Aug 3. Biol Blood Marrow Transplant. 2007. PMID: 17889355 Free PMC article. Clinical Trial.
124 results